Canagliflozin for Chronic Kidney Disease
(CAN-PD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a phase II, proof-of-concept, placebo-controlled, double-blind, cross-over randomized clinical trial, assessing the effect of canagliflozin on peritoneal membrane function in patients on PD.The primary aim of this trial is to determine the short-term effects of canagliflozin, an SGLT-2 inhibitor, on glucose absorption by the peritoneal membrane and on ultrafiltration, as assessed by a standardized peritoneal equilibrium test. The secondary aims are to determine the effect of canagliflozin on solute clearance and on effluent biomarkers of inflammation, angiogenesis, and fibrosis at 26 weeks. We hypothesize that canagliflozin will prevent glucose absorption by the peritoneal membrane, as compared with placebo, and will attenuate the development of inflammation, angiogenesis, and fibrosis of the peritoneal membrane, as assessed by relevant biomarkers in the dialysate.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications like digoxin, phenobarbital, phenytoin, rifampin, or ritonavir if they cannot be safely discontinued. For other medications, the protocol does not specify, so it's best to discuss with the trial team.
Is canagliflozin safe for humans?
Canagliflozin has been shown to be generally safe in humans, with known side effects like genital infections and a noted increased risk of amputations that needs more study. It has been used in people with type 2 diabetes and chronic kidney disease, showing benefits for heart and kidney health.12345
How is the drug canagliflozin unique for treating chronic kidney disease?
Canagliflozin is unique because it is a sodium glucose co-transporter 2 inhibitor that not only lowers blood sugar in type 2 diabetes but also offers kidney protection by promoting the excretion of glucose through urine. This dual action makes it different from traditional treatments that primarily focus on blood pressure control to slow kidney disease progression.34567
What data supports the effectiveness of the drug Canagliflozin for chronic kidney disease?
Who Is on the Research Team?
Thomas A. Mavrakanas, MD, MSc.
Principal Investigator
Research Institute-McGill University of Health Centre
Are You a Good Fit for This Trial?
This trial is for patients on peritoneal dialysis who may have conditions like chronic kidney disease or renal disease. Participants should not have contrast-induced nephropathy or thyroid fibrosis. The study seeks individuals to test the effects of a drug called Canagliflozin.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive canagliflozin or placebo for 5 weeks, followed by crossover to the alternate treatment for another 5 weeks, and then canagliflozin for 16 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Canagliflozin
Find a Clinic Near You
Who Is Running the Clinical Trial?
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator